What is MapLight Therapeutics, Inc. 's restricted cash?

MapLight Therapeutics, Inc. (MPLT) reported restricted cash of $207K in Q1 2026.

What does restricted cash mean?

Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

MapLight Therapeutics, Inc. MPLT Restricted Cash

Restricted Cash at other companies

Acadia PharmaceuticalsACAD

$7.85M-10.5%

MeiraGTx Holdings plcMGTX

$2.22M+6.2%

Taysha Gene Therapies, Inc.TSHA

$449K0.0%

Rapport Therapeutics, Inc.RAPP

$105K0.0%

Neurocrine BiosciencesNBIX

——

Praxis Precision Medicines, Inc.PRAX

——

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B—

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's restricted cash?: MapLight Therapeutics, Inc. (MPLT) reported restricted cash of $207K in Q1 2026.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.